Idebenone (IDBN) is chemically known as 6-(10-hydroxyindenyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone as a yellow crystal or crystalline powder. , no smell. Very difficult to dissolve in water, very soluble in chloroform, methanol or absolute ethanol, soluble in ethyl acetate, difficult to dissolve in n-hexane. It is an intelligent promotion drug developed and released by Takeda Pharmaceutical Co., Ltd. in Japan in 1986; it has an activation effect on the linear pull function, improves brain function metabolism and brain dysfunction, improves the utilization of glucose in the brain, and promotes ATP. It can improve the metabolism of neurotransmitter serotonin in the brain, and has strong anti-oxidation and free radical scavenging effects. It is mainly used in the treatment of degenerative diseases of the central nervous system related to oxidative stress, such as Parkinson's disease, Alzheimer's disease, multi-infarct dementia, regional cerebral anemia and brain failure. It is also used in Friedreich. The treatment of ataxia disorders can also be used in cosmetic formulations, which have the efficacy of scavenging free radicals, inhibiting lipid peroxidation, inhibiting inflammation, inhibiting DNA damage, photoprotection, and reducing pigmentation.

Brain damage caused by diarrhea, chronic cerebrovascular disease and brain trauma. It can improve mental behavioral disorders such as subjective symptoms, language, anxiety, depression, memory loss, and mental decline. [1]
Idebenone is a new type of anti-allergic dementia drug and brain function metabolism and psychotic symptom improving drug. It can improve the metabolism of brain energy, improve brain function, and have a mild antihypertensive effect. Clinically used in patients with cerebral infarction, cerebral hemorrhage and sequelae of arteriosclerosis, brain dysfunction, low consciousness, emotional disorders, language disorders, dementia and other patients. This product has a strong anti-oxidation effect, and idebenone is the most effective external antioxidant in the existing products, and it is one of the best known varieties.
Developed by Japan Takeda Pharmaceutical Industry Co., Ltd., and listed in December 1988. Idebenone is a new type of anti-aging dementia special drug and brain function metabolism and psychotic symptom improving drug, and has a mild antihypertensive effect. It can activate brain mitochondrial respiratory activity, improve brain energy metabolism in cerebral ischemia, improve glucose utilization in brain, increase ATP production in brain, inhibit lipid peroxidation in brain mitochondria, and inhibit lipid peroxidation in brain mitochondrial membrane Membrane barrier. Clinically used in patients with cerebral infarction, cerebral hemorrhage and sequelae of arteriosclerosis, brain dysfunction, low consciousness, emotional disorders, language disorders, dementia and other patients. The toxicity and side effects are low.